Dogwood Therapeutics, Inc. announced a registered direct offering of common stock priced at $8.26 per share under Nasdaq rules, expected to generate approximately $4.8 million in gross proceeds. The company plans to use the net proceeds to further advance the clinical development of its lead development candidate, Halneuron®, and for working capital and general corporate purposes.
Company Information
Company
Dogwood Therapeutics
Location
Atlanta, Georgia, United States
About
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The company's research pipeline includes a non-opioid analgesic program and an antiviral program. Their lead candidate, Halneuron®, is designed to reduce pain from cancer and chemotherapy-induced neuropathic pain. Dogwood Therapeutics is dedicated to advancing treatments for diseases related to reactivated herpes viruses.
AtlantaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma